SEOUL - South Korea has to quickly begin reimbursement of immuno-oncology drugs even if it is just for certain limited patient populations, in order to improve patients’ access and ease their financial burden, experts say.
Despite the government’s move to expand reimbursement of therapies for serious diseases including cancer, authorities appear to be hesitant in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?